Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer

Fuente: Wiley Open Access
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Yuki Teramoto, Ying Wang, Hiroshi Miyamoto
Format: Artículo Open Access
Veröffentlicht: Wiley 2026
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1867010545815650304
author Yuki Teramoto
Ying Wang
Hiroshi Miyamoto
author_facet Yuki Teramoto
Ying Wang
Hiroshi Miyamoto
Yuki Teramoto
Ying Wang
Hiroshi Miyamoto
collection Wiley Open Access
contents Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer Yuki Teramoto Ying Wang Hiroshi Miyamoto BJUI Compass Abstract Objective Perineural invasion (PNI) detected on prostate needle biopsy is a well‐established indicator of adverse pathology, while the prognostic role of PNI quantification has recently been suggested. We herein aimed to determine whether PNI quantification could universally stratify risks by separately assessing subgroups of patients based on biopsy Grade Group (GG). Methods We quantified actual PNI foci in the entire systematic sextant biopsy specimens from 840 men, including 580 (69.0%) exhibiting no PNI and evaluated long‐term oncologic outcomes following radical prostatectomy. Results PNI was detected in 1 (n = 177; 21.1%), 2 (n = 48; 5.7%) or 3–6 (n = 35; 4.2%) of 6 biopsy sites/parts, while 1 (n = 156; 18.6%), 2 (n = 53; 6.3%) or 3–10 (n = 51; 6.1%) PNI foci were present on each biopsy. In the entire cohort, we confirmed a significantly higher risk of biochemical recurrence in patients with PNI (vs. no PNI; P  < 0.001), multi‐site PNI (vs. single‐site PNI; P  < 0.001) or multifocal PNI (vs. unifocal PNI; P  < 0.001). In subgroup analyses, significant differences in the risk of postoperative recurrence between the absence vs. presence of PNI were observed only in patients with GG3 or GG4 cancer. In contrast, the prognostic distinction between single‐site vs. multi‐site PNI or unifocal vs. multifocal PNI was evident in patients with GG2 or GG3 cancer, but not in those with GG1 or GG4–5 cancer. In multivariable analysis, multifocal PNI, but not multi‐site PNI, was independently associated with worse recurrence‐free survival in the GG2 (hazard ratio 5.866, P  = 0.004) and GG3 (hazard ratio 2.716, P  = 0.021) groups. Meanwhile, PNI on prostatectomy was confirmed in 98.1% of biopsy PNI‐positive cases but was still detected in 72.2% of biopsy PNI‐negative cases. Conclusion Quantification of actual PNI foci across all systematic biopsy sites may provide valuable prognostic information, particularly in patients with GG2–3 cancer. Notably, the mere presence of biopsy PNI may not universally predict poorer outcomes. 10.1002/bco2.70196 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1002/bco2.70196
format Artículo Open Access
id wiley_oa_10_1002_bco2_70196
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
Yuki Teramoto
Ying Wang
Hiroshi Miyamoto
BJUI Compass
Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer Yuki Teramoto Ying Wang Hiroshi Miyamoto BJUI Compass Abstract Objective Perineural invasion (PNI) detected on prostate needle biopsy is a well‐established indicator of adverse pathology, while the prognostic role of PNI quantification has recently been suggested. We herein aimed to determine whether PNI quantification could universally stratify risks by separately assessing subgroups of patients based on biopsy Grade Group (GG). Methods We quantified actual PNI foci in the entire systematic sextant biopsy specimens from 840 men, including 580 (69.0%) exhibiting no PNI and evaluated long‐term oncologic outcomes following radical prostatectomy. Results PNI was detected in 1 (n = 177; 21.1%), 2 (n = 48; 5.7%) or 3–6 (n = 35; 4.2%) of 6 biopsy sites/parts, while 1 (n = 156; 18.6%), 2 (n = 53; 6.3%) or 3–10 (n = 51; 6.1%) PNI foci were present on each biopsy. In the entire cohort, we confirmed a significantly higher risk of biochemical recurrence in patients with PNI (vs. no PNI; P  < 0.001), multi‐site PNI (vs. single‐site PNI; P  < 0.001) or multifocal PNI (vs. unifocal PNI; P  < 0.001). In subgroup analyses, significant differences in the risk of postoperative recurrence between the absence vs. presence of PNI were observed only in patients with GG3 or GG4 cancer. In contrast, the prognostic distinction between single‐site vs. multi‐site PNI or unifocal vs. multifocal PNI was evident in patients with GG2 or GG3 cancer, but not in those with GG1 or GG4–5 cancer. In multivariable analysis, multifocal PNI, but not multi‐site PNI, was independently associated with worse recurrence‐free survival in the GG2 (hazard ratio 5.866, P  = 0.004) and GG3 (hazard ratio 2.716, P  = 0.021) groups. Meanwhile, PNI on prostatectomy was confirmed in 98.1% of biopsy PNI‐positive cases but was still detected in 72.2% of biopsy PNI‐negative cases. Conclusion Quantification of actual PNI foci across all systematic biopsy sites may provide valuable prognostic information, particularly in patients with GG2–3 cancer. Notably, the mere presence of biopsy PNI may not universally predict poorer outcomes. 10.1002/bco2.70196 http://creativecommons.org/licenses/by/4.0/
title Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
topic BJUI Compass
url https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.70196